Favorable Support, NDA Submission, Conference Schedule, Acquisition Update, and Executive Appointment - Analyst Notes on Allergan, Pfizer, Eli Lilly, Forest and Pharmacyclics

NEW YORK, May 27, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Forest Laboratories, Inc. (NYSE: FRX) and Pharmacyclics, Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2970-100free.

Allergan, Inc. Analyst Notes
On May 20, 2014, Allergan, Inc. (Allergan) announced that it has received strong support from its physician clients, their nurses and office staff members, as well as from patient advocacy groups and medical associations, regarding the Company's rejection of Valeant's unsolicited proposal to acquire Allergan. The Company informed that it has received more than 500 letters expressing appreciation for Allergan's many contributions in the fields of research and development, product innovation, market creation, and physician support and services. Further, some of the letters also suggest the Company to remain an independent company. In addition, Allergan provided EPS guidance, expecting an increase of 20% to 25% and continuous generation of double digit revenue growth in 2015. The Company also expects to produce EPS compounded annual growth of 20% over the next five years. The full analyst notes on Allergan are available to download free of charge at:

http://www.analystsreview.com/2970-AGN-27May2014.pdf

Pfizer Inc. Analyst Notes
On May 16, 2014, Pfizer Inc. (Pfizer) announced that it will submit a NDA with the FDA for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer. The Company intends to submit the NDA early in Q3 2014. Pfizer noted that the decision was based on discussions with the FDA involving the results of PALOMA-1, a randomized, Phase 2 trial that compared palbociclib plus letrozole versus letrozole alone. The full analyst notes on Pfizer are available to download free of charge at:

http://www.analystsreview.com/2970-PFE-27May2014.pdf

Eli Lilly and Company Analyst Notes
On May 22, 2014, Eli Lilly and Company (Eli Lilly) announced its attendance at the 30th Annual Sanford C. Bernstein Strategic Decisions Conference on May 28, 2014. The Company's Chairman, President and CEO, John C. Lechleiter, Ph.D., is scheduled to participate in a fireside chat at 3:00 p.m. EDT. Eli Lilly also noted that a live audio webcast will be available at the Company's Investor website, under the Webcasts & Presentations section, while a replay will also be available for 90 days. The full analyst notes on Eli Lilly are available to download free of charge at:

http://www.analystsreview.com/2970-LLY-27May2014.pdf

Forest Laboratories, Inc. Analyst Notes
On May 22, 2014, Forest Laboratories, Inc. (Forest) announced that Actavis is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. This offering follows the close of the pending acquisition of the Company by Actavis. The Company is soliciting consents from holders of its securities to eliminate its existing contractual registration rights obligations. Forest informed that Consent Solicitations are expected to expire on June 6, 2014 at 5:00 p.m. New York City time. The full analyst notes on Forest are available to download free of charge at:

http://www.analystsreview.com/2970-FRX-27May2014.pdf

Pharmacyclics, Inc. Analyst Notes
On May 20, 2014, Pharmacyclics, Inc. (Pharmacyclics) announced the appointment of Gregory R. Wade as the Company's Executive Vice President of Business Development. Under the new role, Wade will be responsible for further establishing the Business Development department and leading all Business Development and Competitive Intelligence efforts. Prior to joining Pharmacyclics, Wade was Managing Director of Healthcare Equity Research at Wedbush Pac Grow Life Sciences. The full analyst notes on Pharmacyclics are available to download free of charge at:

http://www.analystsreview.com/2970-PCYC-27May2014.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED